Neptune Technologies & Bioressources Announces Redemption of Debentures Held by Desjardins
Thursday, February 23 2006

Neptune Technologies & Bioressources Announces Redemption of Debentures Held by Desjardins

Laval, Quebec, Canada, February 23rd, 2006 - Neptune Technologies & Bioressources Inc., « Neptune » (TSX Venture Exchange: NTB), announces that, in connection with the closing of Neptune’s previously announced financing, which resulted in gross proceeds of CDN$4.1 million, Neptune has completed the redemption of the debentures issued to Desjardins in October 2003, representing an aggregate of $1,000,000 in principal and $350,136 in interest, such redemption being effected by way of a cash payment to Desjardins.

Neptune has now completely eliminated its $5.6 million debenture debt, which in turn removes $750,000 in annual interest expense.

“We are pleased with our capital reorganization and the elimination of Neptune’s long term debenture. The Desjardins cash payment has no dilutive effect to shareholders” said André Godin, Vice President Administration and Finance at Neptune Technologies & Bioressources Inc. “We expect the $750,000 per annum to expedite Neptune’s growth and drastically increase net income.”

About Neptune Technologies & Bioressources Inc. https://www.neptunebiotech.com/
Neptune Technologies & Bioressources Inc. develops high value added nutritional products from underexploited marine biomasses, such as krill, with its patented extraction process (Neptune OceanExtract™). Using an exclusive process, Neptune Technologies & Bioressources Inc. is well positioned in the $182 billion global nutrition market (Nutrition Business Journal, Oct/Nov 2004) of health and wellness concepts.

Natural biomass extraction is now playing an important role in developing nutrigenomics, the next wave in nutritional research. Through strategic alliances and partnerships, as well as through clinical studies, the Company continues to demonstrate the immense beneficial effects of these products. The Company develops and markets new formulas and new products for specific applications in high growth markets such the nutraceutical, cosmeceutical, biopharmaceutical and nutrigenomics markets.

Neither NASDAQ nor TSX venture exchange accepts responsibility for the adequacy or accuracy of this press release.
Neptune Technologies and Acasti Pharma Contact:
Neptune Technologies & Bioressources Inc.
Acasti Pharma Inc.
Toni Rinow, Ph.D., MBA
Corporate Development & Investor Relations
(450) 687-2262
This e-mail address is being protected from spambots, you need JavaScript enabled to view it
# # #
Statements in this press release that are not statements of historical or current fact constitute "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and Canadian securities laws. Such forward-looking statements involve known and unknown risks, uncertainties, and other unknown factors that could cause the actual results of the Company to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. In addition to statements which explicitly describe such risks and uncertainties, readers are urged to consider statements labeled with the terms "believes," "belief," "expects," "intends," "anticipates," "will," or "plans" to be uncertain and forward-looking. The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in the Company's reports filed with the Securities and Exchange Commission and the Canadian securities commissions.
< Prev   Next >
 
back to press releases list

We communicate

NTB (TSX) CAN$ 1.93 +0.03
NEPT (NASDAQ) US$ 1.898 +0.068
 

press releases

Neptune subsidiary Acasti reports superior effect of Drug Candidate CaPre over Lovaza
 
Neptune Appoints IR firm for the US
 

Investor Relations Contact NEPTUNE TECHNOLOGIES & BIORESSOURCES